Review Article| Volume 34, ISSUE 3, P637-654, September 2014

Perioperative Management of Patients Receiving New Oral Anticoagulants

An International Survey


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Heidbuchel H.
        • Verhamme P.
        • Alings M.
        • et al.
        EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.
        Eur Heart J. 2013; 34: 2094-2106
        • Gallego P.
        • Roldan V.
        • Lip G.Y.
        Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
        Am J Respir Crit Care Med. 2013; 188: 413-421
        • Kwok C.S.
        • Pradhan S.
        • Yeong J.K.
        • et al.
        Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
        Chest. 2013; 144: 593-600
      1. Bayer Pharma AG. Rivaroxaban summary of product characteristics. Available at: Accessed December 9, 2013.

        • Eikelboom J.W.
        • Weitz J.I.
        New anticoagulants.
        Circulation. 2010; 121: 1523-1532
        • Samama M.M.
        • Amiral J.
        • Guinet C.
        • et al.
        Monitoring plasma levels of factor Xa inhibitors: how, why and when?.
        Expert Rev Hematol. 2013; 6: 155-164
        • Samama M.M.
        • Guinet C.
        • Le Flem L.
        • et al.
        Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.
        J Thromb Thrombolysis. 2013; 35: 140-146
        • Kaatz S.
        • Crowther M.
        Reversal of target-specific oral anticoagulants.
        J Thromb Thrombolysis. 2013; 36: 195-202
        • Spyropoulos A.C.
        • Douketis J.D.
        How I treat anticoagulated patients undergoing an elective procedure or surgery.
        Blood. 2012; 120: 2954-2962
        • Levy J.H.
        • Faraoni D.
        • Spring J.L.
        • et al.
        Managing new oral anticoagulants in the perioperative and intensive care unit setting.
        Anesthesiology. 2013; 118: 1466-1474
        • Fawole A.
        • Daw H.A.
        • Crowther M.A.
        Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
        Cleve Clin J Med. 2013; 80: 443-451
        • Sie P.
        • Samama C.M.
        • Godier A.
        • et al.
        Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.
        Arch Cardiovasc Dis. 2011; 104: 669-676
        • Kozek-Langenecker S.A.
        • Afshari A.
        • Albaladejo P.
        • et al.
        Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology.
        Eur J Anaesthesiol. 2013; 30: 270-382
        • Spahn D.R.
        • Bouillon B.
        • Cerny V.
        • et al.
        Management of bleeding and coagulopathy following major trauma: an updated European guideline.
        Crit Care. 2013; 17: R76
        • Steiner T.
        • Bohm M.
        • Dichgans M.
        • et al.
        Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
        Clin Res Cardiol. 2013; 102: 399-412
        • Ferrandis R.
        • Castillo J.
        • de Andres J.
        • et al.
        The perioperative management of new direct oral anticoagulants: a question without answers.
        Thromb Haemost. 2013; 110: 515-522
        • Pernod G.
        • Albaladejo P.
        • Godier A.
        • et al.
        Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP).
        Arch Cardiovasc Dis. 2013; 106: 382-393
        • Guyatt G.
        • Eikelboom J.W.
        • Akl E.A.
        • et al.
        A guide to GRADE guidelines for the readers of JTH.
        J Thromb Haemost. 2013; 11: 1603-1608
        • Marlu R.
        • Hodaj E.
        • Paris A.
        • et al.
        Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
        Thromb Haemost. 2012; 108: 217-224
        • Healey J.S.
        • Eikelboom J.
        • Douketis J.
        • et al.
        Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial.
        Circulation. 2012; 126: 343-348
        • Braithwaite D.
        • Emery J.
        • De Lusignan S.
        • et al.
        Using the Internet to conduct surveys of health professionals: a valid alternative?.
        Fam Pract. 2003; 20: 545-551
        • Mavis B.E.
        • Brocato J.J.
        Postal surveys versus electronic mail surveys. The tortoise and the hare revisited.
        Eval Health Prof. 1998; 21: 395-408
        • Cannesson M.
        • Pestel G.
        • Ricks C.
        • et al.
        Hemodynamic monitoring and management in patients undergoing high risk surgery: a survey among North American and European anesthesiologists.
        Crit Care. 2011; 15: R197
        • Vandermeulen E.
        • Decoster J.
        • Dewandre P.Y.
        • et al.
        Central neural blockade in patients with a drug-induced alteration of coagulation. Third edition of the Belgian Association for Regional Anaesthesia (BARA) Guidelines.
        Acta Anaesthesiol Belg. 2011; 62: 175-191
        • Levy J.H.
        • Key N.S.
        • Azran M.S.
        Novel oral anticoagulants: implications in the perioperative setting.
        Anesthesiology. 2010; 113: 726-745
        • Horlocker T.T.
        • Wedel D.J.
        • Rowlingson J.C.
        • et al.
        Executive summary: regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition).
        Reg Anesth Pain Med. 2010; 35: 102-105
        • Gogarten W.
        • Vandermeulen E.
        • Van Aken H.
        • et al.
        Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology.
        Eur J Anaesthesiol. 2010; 27: 999-1015
        • Llau J.V.
        • Ferrandis R.
        New anticoagulants and regional anesthesia.
        Curr Opin Anaesthesiol. 2009; 22: 661-666
        • Rosencher N.
        • Bonnet M.P.
        • Sessler D.I.
        Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies.
        Anaesthesia. 2007; 62: 1154-1160